Trump/Cook, Nissan weakness, more tariffs and gold - what’s moving markets
ZUG, Switzerland - Pharvaris (NASDAQ:PHVS), a $910 million market cap biotech company with a strong financial health score according to InvestingPro, presented data on its oral bradykinin B2 receptor antagonist deucrictibant for treating hereditary angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress 2025, according to a company press release.
The data showed deucrictibant maintained sustained attack reduction and improved quality of life measures in the CHAPTER-1 study’s open-label extension. In the RAPIDe-2 on-demand long-term extension study, the drug demonstrated early-onset symptom relief with a median time of 1.1 hours and complete resolution in 86.9% of attacks at 24 hours. The company maintains a healthy balance sheet with more cash than debt and a robust current ratio of 11.1, though InvestingPro data indicates rapid cash burn rates typical of clinical-stage biotechs.
For upper airway attacks specifically, the median time to symptom relief was 1.4 hours, with 92.9% of these attacks requiring only a single dose of deucrictibant.
The company also highlighted that its ongoing RAPIDe-3 Phase 3 on-demand study will explore "end-of-progression" as a new pre-specified endpoint to assess the full impact of deucrictibant on HAE attacks.
Additional data showed deucrictibant’s potential for treating acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), for which there are currently no approved therapies.
Pharvaris is developing two oral formulations of deucrictibant: an extended-release tablet for prophylactic treatment and an immediate-release capsule for on-demand treatment. The drug has received orphan drug designation from both U.S. and European regulatory authorities.
The company is currently conducting Phase 3 studies evaluating deucrictibant for both prevention (CHAPTER-3) and on-demand treatment (RAPIDe-3) of HAE attacks. With four analysts recently revising earnings estimates upward and the stock showing counter-market movement tendencies with a beta of -2.86, investors can access more detailed analysis and 6 additional ProTips through InvestingPro.
In other recent news, Pharvaris announced promising developments concerning its drug candidate deucrictibant, designed for bradykinin-mediated angioedema. The company shared new data indicating that deucrictibant could effectively prevent and treat hereditary angioedema (HAE) attacks, with ongoing studies showing promising results in maintaining low attack rates over extended periods. Additionally, Pharvaris received orphan designation from the European Commission for deucrictibant, following a similar acknowledgment by the U.S. Food and Drug Administration. The company is actively conducting Phase 3 trials to further evaluate the drug’s efficacy and safety for both prophylactic and on-demand use. Analysts at JMP Securities reiterated their Market Outperform rating for Pharvaris, maintaining a price target of $55, citing the company’s strategic positioning and upcoming milestones in the HAE market. They highlighted the potential for significant developments with the anticipated Phase 3 data for deucrictibant expected in 2026. The analysts also projected peak sales estimates reaching approximately $600 million for acute treatment and around $1.6 billion for prophylactic use. Pharvaris is planning to initiate a new Phase 3 trial for deucrictibant in acquired angioedema within this year, aiming to broaden its application beyond existing indications. These developments underscore the company’s commitment to addressing unmet needs in angioedema treatments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.